Cafepharma Today

May 16 2025 - Novo CEO to depart as obesity drugmaker’s challenges rise
Novo CEO to depart as obesity drugmaker’s challenges rise
BioMarin expands enzyme expertise with $270M Inozyme buy
Amgen could owe Regeneron more than $400M after defeat in cholesterol drug antitrust suit
Eli Lilly collaborates with Rznomics on hearing loss treatment in $1.3 billion pact
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Gilead Sciences: Sovaldi Sales Slip But Less Than Feared
Barron's
Friday, September 12, 2014 - 6:58pm
tags:
Gilead Sciences, Sovaldi, hepatitis C
Pfizer CEO is Still Weighing Inversion Deals
WSJ Online
Friday, September 12, 2014 - 6:57pm
tags:
Pfizer, Ian Read, Pharma CEOs, tax inversions, M&A, AstraZeneca, Actavis
Abbott, Medtronic named among world's greenest companies
Mass Device
Friday, September 12, 2014 - 10:40am
tags:
Abbott Labs, Medtronic, devices, environmental concerns
Third Time Was No Charm, FDA Denies Amarin Vascepa SPA Appeal
TheStreet.com
Friday, September 12, 2014 - 10:38am
tags:
FDA, Amarin, Vascepa
Lilly colon cancer drug succeeds in late stage study
Yahoo/Reuters
Friday, September 12, 2014 - 10:23am
tags:
Eli Lilly, colon cancer, ramucirumab
Novartis reports positive data for Gilenya in key measures of MS disease activity
First Word Pharma
Friday, September 12, 2014 - 10:22am
tags:
Novartis, Gilenya, MS, multiple sclerosis
Ackman Gets Growing Shareholder Support In Allergan-Valeant Battle
Bidness Etc.
Friday, September 12, 2014 - 9:56am
tags:
Allergan, Bill Ackman, Valeant Pharmaceuticals, M&A
Oxygen halts work on brain injury drug over enrollment woes
Fierce Biotech
Friday, September 12, 2014 - 9:55am
tags:
Oxygen Biotherapeutics, Oxycyte, traumatic brain injury
Merck's Keytruda is shipping
Medical Marketing and Media
Friday, September 12, 2014 - 8:48am
tags:
Merck, Keytruda, anti-PD-1 immunotherapy
Biogen Shows Positive Effects in Year Two of RMS Drug Trial
Drug Discovery and Development
Friday, September 12, 2014 - 8:47am
tags:
Biogen Idec, Plegridy, RMS
Safety warnings will hold back new obesity treatment Contrave
Pharmaphorum
Friday, September 12, 2014 - 8:41am
tags:
Orexigen, Takeda, obesity, Contrave
Novartis commits $20M to build a new CAR-T development center at Penn
Fierce Biotech
Friday, September 12, 2014 - 8:39am
tags:
Novartis, R&D, CAR-T
Japanese Research Scandal Involving Novartis Blood Pressure Drug Widens
Forbes
Friday, September 12, 2014 - 8:33am
tags:
Novartis, Japan, Diovan
Medtronic Looking To Boost Cardiovascular Therapeutic Revenue
Bidness Etc.
Friday, September 12, 2014 - 8:29am
tags:
Medtronic, devices, NC Euphora
Merck KGaA ends lung cancer vaccine trials
Yahoo/Reuters
Friday, September 12, 2014 - 8:27am
tags:
Merck KGaA, lung cancer, vaccines, Stimuvax
India's Lupin in deal to market U.S. firm Salix's drugs in Canada
Yahoo/Reuters
Friday, September 12, 2014 - 8:17am
tags:
Lupin, Salix, India, Canada
Pfizer confirms that it has dropped the idea of acquiring AstraZeneca; is now eyeing other viable acquisitions such as Actavis
Bidness Etc.
Friday, September 12, 2014 - 8:06am
tags:
Pfizer, AstraZeneca, M&A, Actavis
Google's stealthy Calico inks an R&D deal for new compounds aimed at neurodegeneration
Fierce Biotech
Thursday, September 11, 2014 - 5:24pm
tags:
Google, Calico, R&D, neurodegenerative disease
Ebola-Stricken Doc Receives Experimental Drug, But Which One?
TheStreet.com
Thursday, September 11, 2014 - 5:22pm
tags:
ebola virus, Tekmira Pharmaceuticals, TKM-EBOLA
Orexigen's Obesity Pill is Approved and Stock Falls. Don't be Surprised
TheStreet.com
Thursday, September 11, 2014 - 5:21pm
tags:
Orexigen, Contrave, FDA, obesity

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.